A new treatment for advanced breast cancer might soon be available on the NHS, as it has been approved by the National Institute for Health and Care Excellent (NICE).

The tablet capivasertib, used alongside fulvestrant, has been approved for those with hormone receptor-positive, HER2-negative breast cancer that has progressed following endocrine treatment.

Trials have suggested that patients who take capiversatib with fulvestrant have, on average, an extra four months before their condition progressed compared to taking just fulvestrant alone.

Professor Peter Johnson, national clinical director for cancer at NHS England, said: “This new combination treatment offers an additional option for some people whose breasts cancer has progressed despite previous hormone therapy, and who may benefit from a targeted approach.

“While it won’t be suitable for everyone, giving patients more time before more intensive therapies are required is an important part of our drive to personalise cancer care and improve quality of life for patients wherever possible.”